Evaluation of the cytotoxic and immunogenic potential of temozolamide, panabinostat, and Lophophora williamsii extract against C6 glioma cells

Franco‐Molina, Moises Armides; Santana-Krímskaya, Silvia Elena; Madrigal-de-León, Luis Mario; Coronado‐Cerda, Erika Evangelina; Zárate-Triviño, Diana; Hernández-Martínez, Sara Paola; García-Coronado, Paola Leonor; Rodríguez‐Padilla, Cristina

doi:10.17179/excli2020-3181

Cited by 7 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amidst the pharmaceutical therapies available for the treatment of glioma and melanoma, we can find the well-known drug temozolomide (TMZ), an oral DNA alkylating agent. 105,127 A study unveiled that the incorporation of a N-ethylselenocyanate group to the amide functionality of TMZ resulted in 40 (Figure 9) that exerted a stronger antitumor activity in both glioma and melanoma mouse models. 105 Of note, this modification did not affect its capacity to penetrate the blood−brain barrier (BBB), as the moiety responsible for this TMZ property and the degradation of active metabolites remains unmodified.…”

Section: Cytarabinementioning

confidence: 99%

Selenization of Small Molecule Drugs: A New Player on the Board

Morán-Serradilla,

Plano,

Sanmartín

et al. 2024

J. Med. Chem.

View full text Add to dashboard Cite

There is an urgent need to develop safer and more effective modalities for the treatment of a wide range of pathologies due to the increasing rates of drug resistance, undesired side effects, poor clinical outcomes, etc. Throughout the years, selenium (Se) has attracted a great deal of attention due to its important role in human health. Besides, a growing body of work has unveiled that the inclusion of Se motifs into a great number of molecules is a promising strategy for obtaining novel therapeutic agents. In the current Perspective, we have gathered the most recent literature related to the incorporation of different Se moieties into the scaffolds of a wide range of known drugs and their feasible pharmaceutical applications. In addition, we highlight different representative examples as well as provide our perspective on Se drugs and the possible future directions, promises, opportunities, and challenges of this ground-breaking area of research. ■ SIGNIFICANCE • Significance: The development of novel compounds for the treatment of numerous pathologies has become a priority due to the lack of effective therapeutic options. • Impact: This work highlights the potential of incorporating Se moieties into the scaffold of several drugs to develop novel safer bioactive compounds. • Innovation: This Perspective discusses the development of selenoderivatives of a wide array of drugs and their biological applications and proposes novel avenues to continue exploring this outstanding research area.

show abstract

Section: Cytarabinementioning

confidence: 99%

Selenization of Small Molecule Drugs: A New Player on the Board

Morán-Serradilla,

Plano,

Sanmartín

et al. 2024

J. Med. Chem.

View full text Add to dashboard Cite

show abstract

“…HDACi appear to have a vital role in DNA damage response, and a radiosensitizing effect of HDACi (vorinostat, panobinostat, VPA, entinostat, scriptaid) has been shown in GB in vitro, with support for vorinostat for GB therapy in combination with heavy ion therapy [ 31 , 33 , 35 , 128 ]. HDACi have been shown to inhibit GB cell growth mediated by cell cycle arrest and apoptosis, as highlighted in Supplementary Table S1 [ 129 , 130 , 131 , 132 , 133 , 134 , 135 ]. The class I/II HDACi trichostatin A (TSA) increased GB apoptosis induction through the p38MAPK-p53 cascade [ 136 ].…”

Section: Current Status Of Hdaci For Gb Therapymentioning

confidence: 99%

Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy

et al. 2023

View full text Add to dashboard Cite

Despite recent advances in multimodality therapy for glioblastoma (GB) incorporating surgery, radiotherapy, chemotherapy and targeted therapy, the overall prognosis remains poor. One of the interesting targets for GB therapy is the histone deacetylase family (HDAC). Due to their pleiotropic effects on, e.g., DNA repair, cell proliferation, differentiation, apoptosis and cell cycle, HDAC inhibitors have gained a lot of attention in the last decade as anti-cancer agents. Despite their known underlying mechanism, their therapeutic activity is not well-defined. In this review, an extensive overview is given of the current status of HDAC inhibitors for GB therapy, followed by an overview of current HDAC-targeting radiopharmaceuticals. Imaging HDAC expression or activity could provide key insights regarding the role of HDAC enzymes in gliomagenesis, thus identifying patients likely to benefit from HDACi-targeted therapy.

show abstract

“…Nanozyme-catalyzed chemodynamical therapy showed great potential due to its noninvasion, sensitive tumor cell lethal, and immunity regulation . Moreover, CDT, if it synergized with photothermal therapy, could be augmented with improved therapeutic outcomes.…”

mentioning

confidence: 99%

“…30,31 Standard treatment for glioma is surgical resection followed by radiotherapy and chemotherapy using TMZ (a secondgeneration oral alkylating agent, which cannot induce ICD when applied alone). 32 For GBM, the effect of treatment is poor, and there are considerable side effects. Most patients still need to undergo secondary surgery.…”

mentioning

confidence: 99%

“…Nanozyme-catalyzed chemodynamical therapy showed great potential due to its noninvasion, sensitive tumor cell lethal, and immunity regulation. 32 Moreover, CDT, if it synergized with photothermal therapy, could be augmented with improved therapeutic outcomes. In spite of this, the current strategy to combine CDT and PTT remains in several dilemmas when it was used for glioma treatment.…”

mentioning

confidence: 99%

See 1 more Smart Citation

In Situ Attached Photothermal Immunomodulation-Enhanced Nanozyme for the Inhibition of Postoperative Malignant Glioma Recurrence

Nie

Ling

et al. 2023

ACS Nano

View full text Add to dashboard Cite

Glioblastoma (GBM) is one of the most challenging malignant brain tumors to treat. Herein, we describe a nanoenzyme hemostatic matrix strategy with the tumor cavity in situ application that simultaneously serves as photothermal agent and induces immunogenic cell death after GBM surgical resection to enhance the antitumor immunity and delay tumor recurrence. The hemostatic matrix system (Surgiflo@PCN) contains Surgiflo, a multispace structure that can be used to penetrate different shapes of tumor cavities to prevent postoperative tumor cavity hemorrhage. As well, porous palladium−copper nanoclusters (PCNs) have adjustable enzyme-like activities (oxidase, peroxidase, and catalase) responsible for formation of reactive oxygen species (ROS) under near-infrared (808 nm) laser irradiation. When the Surgiflo@PCN entered the resected tumor cavity, the first action was the direct killing of glioma cells via ROS and photothermal therapy (PTT). The second action was the induction of immunogenic cell death by PCN-enhanced oxidative stress and PTT, which reversed the immunosuppressive tumor microenvironment and enhanced the antitumor immune response. This eradicated residual glioma cells and prevented recurrence. The collective findings demonstrate that Surgiflo@ PCN kills glioma cells directly through ROS and PTT and enhances antiglioma immunity and kills glioma cells indirectly. The "one-stone, two-birds" strategy could become an effective photothermal immunotherapy in GBM patients.

show abstract

Evaluation of the cytotoxic and immunogenic potential of temozolamide, panabinostat, and Lophophora williamsii extract against C6 glioma cells

Cited by 7 publications

References 21 publications

Selenization of Small Molecule Drugs: A New Player on the Board

Selenization of Small Molecule Drugs: A New Player on the Board

Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy

In Situ Attached Photothermal Immunomodulation-Enhanced Nanozyme for the Inhibition of Postoperative Malignant Glioma Recurrence

Contact Info

Product

Resources

About